SV2016005312A - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer

Info

Publication number
SV2016005312A
SV2016005312A SV2016005312A SV2016005312A SV2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A SV 2016005312 A SV2016005312 A SV 2016005312A
Authority
SV
El Salvador
Prior art keywords
compounds
salts
ona
quinolin
descriptive memory
Prior art date
Application number
SV2016005312A
Other languages
English (en)
Inventor
Bernard Christophe Barlaamm
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2016005312A publication Critical patent/SV2016005312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA MEMORIA DESCRIPTIVA SE REFIERE GENERALMENTE A LOS COMPUESTOS DE FÓRMULA (I): (VER FORMULA); Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, DONDE Q, R1, R2, R3, R4 Y R5 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN LA PRESENTE. LA MEMORIA DESCRIPTIVA TAMBIÉN SE REFIERE AL USO DE TALES COMPUESTOS Y SALES DE ESTOS PARA TRATAR O PREVENIR ENFERMEDADES MEDIADAS POR LA CINASA ATM, INCLUYENDO EL C�NCER. LA MEMORIA DESCRIPTIVA ADEM�S SE REFIERE A LAS FORMAS CRISTALINAS DE LOS COMPUESTOS DE COMPUESTOS IMIDAZO[4,5-C]QUINOLIN-2-ONA Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS; LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y SALES; LOS KITS QUE COMPRENDEN TALES COMPUESTOS Y SALES; LOS MÉTODOS DE FABRICACIÓN DE TALES COMPUESTOS Y SALES; LOS INTERMEDIOS ÚTILES EN LA FABRICACIÓN DE TALES COMPUESTOS Y SALES; Y LOS MÉTODOS PARA TRATAR ENFERMEDADES MEDIADAS POR LA CINASA ATM, INCLUYENDO EL C�NCER, UTILIZANDO TALES COMPUESTOS Y SALES
SV2016005312A 2014-05-08 2016-11-08 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer SV2016005312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
SV2016005312A true SV2016005312A (es) 2017-03-16

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005312A SV2016005312A (es) 2014-05-08 2016-11-08 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer

Country Status (38)

Country Link
US (4) US9428503B2 (es)
EP (1) EP3140303B1 (es)
JP (1) JP6505131B2 (es)
KR (1) KR102013021B1 (es)
CN (1) CN106255692B (es)
AP (1) AP2016009532A0 (es)
AR (1) AR100340A1 (es)
AU (1) AU2015257456B2 (es)
CA (1) CA2946459C (es)
CL (1) CL2016002735A1 (es)
CR (1) CR20160523A (es)
CY (1) CY1120248T1 (es)
DK (1) DK3140303T3 (es)
DO (1) DOP2016000281A (es)
EA (1) EA031674B1 (es)
ES (1) ES2670416T3 (es)
HR (1) HRP20180697T1 (es)
HU (1) HUE037558T2 (es)
IL (1) IL248397B (es)
LT (1) LT3140303T (es)
MA (1) MA39960A (es)
MX (1) MX2016014639A (es)
NI (1) NI201600166A (es)
NO (1) NO2714752T3 (es)
NZ (1) NZ726042A (es)
PE (1) PE20170403A1 (es)
PH (1) PH12016502168B1 (es)
PL (1) PL3140303T3 (es)
PT (1) PT3140303T (es)
RS (1) RS57223B1 (es)
SG (1) SG11201609164VA (es)
SI (1) SI3140303T1 (es)
SV (1) SV2016005312A (es)
TN (1) TN2016000458A1 (es)
TR (1) TR201807101T4 (es)
TW (1) TWI662034B (es)
UY (1) UY36112A (es)
WO (1) WO2015170081A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747952A (zh) * 2015-04-02 2020-10-09 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2018011283A (es) * 2016-03-21 2019-05-27 Astrazeneca Ab Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
US20190119270A1 (en) * 2016-04-07 2019-04-25 Astrazeneca Ab N-Oxide Compound and Its Use in Treating Cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112019012217B1 (pt) 2016-12-20 2021-08-10 Astrazeneca Ab Compostos, formas cristalinas, composição farmacêutica e uso de um composto ou seu sal farmaceuticamente aceitável
KR102660196B1 (ko) * 2017-01-09 2024-04-24 임팩트 테라퓨틱스 (상하이), 인코포레이티드 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CA3111994A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2h-imidazo[4,5-c]cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
AU2019360608A1 (en) * 2018-10-15 2021-06-03 Merck Patent Gmbh Combination therapy utilizing DNA alkylating agents and ATR inhibitors
MA55198A (fr) * 2019-03-05 2022-01-12 Astrazeneca Ab Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
US20220259211A1 (en) * 2019-07-10 2022-08-18 Impact Therapeutics (Shanghai), Inc Substituted pyrazoloquinazolinone compounds and application thereof
CA3149883A1 (en) * 2019-09-12 2021-03-18 Sui Xiong Cai Substituted imidazoquinoxaline compounds and uses thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
CN114980900A (zh) * 2020-01-13 2022-08-30 上海华禹生物科技有限公司 N2-喹啉或异喹啉取代的嘌呤衍生物在癌症治疗中的用途
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022193166A1 (en) * 2021-03-17 2022-09-22 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1687305B1 (en) 2003-11-21 2008-07-09 Novartis AG 1h-imidazoquinoline derivatives as protein kinase inhibitors
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GEP20156267B (en) 2009-06-04 2015-04-14 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
CN102803259A (zh) * 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
UA108863C2 (ru) * 2009-09-28 2015-06-25 Ф. Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и их применение
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012026233A1 (ja) 2010-08-26 2012-03-01 日立建機株式会社 建設機械
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
BR112013013837A2 (pt) 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
NO2714752T3 (es) 2018-04-21
CA2946459C (en) 2022-07-12
PT3140303T (pt) 2018-05-25
PH12016502168A1 (en) 2016-12-19
DOP2016000281A (es) 2016-12-15
BR112016025153A8 (pt) 2021-07-20
KR102013021B1 (ko) 2019-08-21
US9822111B2 (en) 2017-11-21
US10189834B2 (en) 2019-01-29
IL248397B (en) 2019-02-28
EA201692095A1 (ru) 2017-08-31
LT3140303T (lt) 2018-05-25
US20180134699A1 (en) 2018-05-17
PH12016502168B1 (en) 2016-12-19
TN2016000458A1 (en) 2018-04-04
ES2670416T3 (es) 2018-05-30
CL2016002735A1 (es) 2017-02-10
TWI662034B (zh) 2019-06-11
CA2946459A1 (en) 2015-11-12
PE20170403A1 (es) 2017-05-07
NI201600166A (es) 2017-03-13
CR20160523A (es) 2017-04-27
AU2015257456B2 (en) 2018-02-15
US20160368920A1 (en) 2016-12-22
HUE037558T2 (hu) 2018-09-28
CY1120248T1 (el) 2019-07-10
BR112016025153A2 (pt) 2017-08-15
JP2017514877A (ja) 2017-06-08
RS57223B1 (sr) 2018-07-31
CN106255692A (zh) 2016-12-21
SI3140303T1 (en) 2018-06-29
UY36112A (es) 2015-10-30
US20190185468A1 (en) 2019-06-20
KR20160147054A (ko) 2016-12-21
EP3140303A1 (en) 2017-03-15
JP6505131B2 (ja) 2019-04-24
MA39960A (fr) 2018-03-28
US20150336952A1 (en) 2015-11-26
US9428503B2 (en) 2016-08-30
DK3140303T3 (en) 2018-06-06
AP2016009532A0 (en) 2016-11-30
HRP20180697T1 (hr) 2018-06-01
SG11201609164VA (en) 2016-12-29
EP3140303B1 (en) 2018-03-28
MX2016014639A (es) 2017-03-06
NZ726042A (en) 2018-08-31
AR100340A1 (es) 2016-09-28
AU2015257456A1 (en) 2016-11-24
TW201625609A (zh) 2016-07-16
PL3140303T3 (pl) 2018-08-31
WO2015170081A1 (en) 2015-11-12
TR201807101T4 (tr) 2018-06-21
EA031674B1 (ru) 2019-02-28
CN106255692B (zh) 2019-02-26

Similar Documents

Publication Publication Date Title
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
DOP2016000140A (es) Inhibidores de syk
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
SV2017005368A (es) [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP18056196A (es) Derivados de indano
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
AR096322A1 (es) Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos